All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the promising new agents for patients with myelofibrosis?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, What are the promising new agents for patients with myelofibrosis?
What are the promising new agents for patients with myelofibrosis?
In this video, Mesa outlines the new agents available for the treatment of patients with myelofibrosis, including the JAK inhibitors ruxolitinib and fedratinib, and another two JAK inhibitors currently under development, momelotinib and pacritinib. Mesa then moves on to discuss other options beyond JAK inhibition, including CPI-0610, navitoclax, imetelstat, bomedemstat, and luspatercept.
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox